9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference

Rhea-AI Summary

9 Meters Biopharma (NASDAQ: NMTR) will present at the 12th Annual Jefferies London Healthcare Conference on November 17, 2021. CEO John Temperato is scheduled to speak from 10:00 to 10:35 a.m. GMT, discussing the company's innovative solutions for rare digestive diseases. Investors can engage in one-on-one meetings in person on November 16-17 or virtually on November 18-19. Key products include vurolenatide for short bowel syndrome and larazotide for celiac disease. A replay of the presentation will be available for 90 days.

• In-Person Dates: November 16^th-17^th
• Virtual Dates: November 18^th-19^th

RALEIGH, NC / ACCESSWIRE / November 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced that the Company's CEO, John Temperato is scheduled to present at the 12^th Annual Jefferies London Healthcare Conference and invites investors to participate in one-on-one meetings both in person on Tuesday and Wednesday November 16^th/17^th or virtually on Thursday and Friday November 18^th/19^th. Please see Live Presentation details below:

12^th Annual Jefferies London Healthcare Conference
Date: Wednesday, November 17^th
Time: 10:00 to 10:35 a.m. GMT
Presenter: John Temperato, CEO of 9Meters Biopharma
Webcast: Registration Link - Click Here

* a replay will be available following the presentation for 90 days

Please contact your Jefferies representative if you would like to participate in either an in-person or virtually format to schedule a one-on-one meeting with 9 Meters during the conference.

For more information about the Jefferies London Healthcare Conference, please refer to the Jefferies conference website.

About 9 Meters Biopharma
9 Meters Biopharma, Inc. is a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology. The Company is advancing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for short bowel syndrome (SBS); larazotide, a Phase 3 tight junction regulator in non-responsive celiac disease; and several other early-stage assets.

For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.

Forward-Looking Statements
This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, anticipated milestones and any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: uncertainties associated with the clinical development and regulatory approval of product candidates; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; the impact of COVID-19 on our operations, enrollment in and timing of clinical trials; risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; reliance on collaborators; and risks associated with acquiring and developing additional compounds. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, Form 10-Q for the quarter ended June 30, 2021, and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Corporate Contacts:
Edward J. Sitar
Chief Financial Officer
9 Meters Biopharma, Inc.
investor-relations@9meters.com
www.9meters.com

Media Contact:
Veronica Eames
LifeSci Communications, LLC
veames@lifescicomms.com
203-942-4626

Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

SOURCE: 9 Meters Biopharma

View source version on accesswire.com:
https://www.accesswire.com/671779/9-Meters-Biopharma-Inc-to-Present-at-the-12th-Annual-Jefferies-London-Healthcare-Conference

FAQ

What is the date of 9 Meters Biopharma's presentation at the Jefferies London Healthcare Conference?

9 Meters Biopharma will present on November 17, 2021.

Who is the presenter for 9 Meters Biopharma at the conference?

CEO John Temperato will present at the conference.

What time will the presentation by 9 Meters Biopharma take place?

The presentation is scheduled from 10:00 to 10:35 a.m. GMT.

How can investors schedule meetings with 9 Meters Biopharma during the conference?

Investors can contact their Jefferies representative to schedule one-on-one meetings.

When are the in-person and virtual meeting dates for the conference?

In-person meetings are on November 16-17, and virtual meetings are on November 18-19.

What are the main products discussed by 9 Meters Biopharma?

The main products include vurolenatide for short bowel syndrome and larazotide for non-responsive celiac disease.